Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias

Autoimmune hemolytic anemia (AIHA) and pure red cell aplasia (PRCA) are common complications of CLL. The optimal treatment of steroid refractory AIHA/PRCA is not well established. We conducted a multicenter study of ibrutinib and rituximab in patients with relapsed/refractory to steroids AIHA/PRCA a...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikitin, Eugene, Kislova, Maria, Morozov, Dmitry, Belyakova, Vera, Suvorova, Anna, Sveshnikova, Julia, Vyscub, Galina, Matveeva, Irina, Shirokova, Maria, Shipaeva, Anna, Klitochenko, Tatyana, Makarovskaya, Polina, Dmitrieva, Elena, Biderman, Bella, Sudarikov, Andrei, Obukhova, Tatyana, Samoilova, Olga, Kaplanov, Kamil, Konstantinova, Tatyana, Mayorova, Olga, Poddubnaya, Irina, Ptushkin, Vadim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195665/
https://www.ncbi.nlm.nih.gov/pubmed/37202442
http://dx.doi.org/10.1038/s41375-023-01891-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195665/
https://www.ncbi.nlm.nih.gov/pubmed/37202442
http://dx.doi.org/10.1038/s41375-023-01891-3

Ejemplares similares